Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Accured Expenses (2016 - 2026)

Lineage Cell Therapeutics has reported Change in Accured Expenses over the past 17 years, most recently at -$1.7 million for Q1 2026.

  • For Q1 2026, Change in Accured Expenses fell 1529.52% year-over-year to -$1.7 million; the TTM value through Mar 2026 reached $665000.0, up 154.87%, while the annual FY2025 figure was $2.3 million, 235.1% up from the prior year.
  • Change in Accured Expenses for Q1 2026 was -$1.7 million at Lineage Cell Therapeutics, down from $2.5 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $2.5 million in Q4 2025 and troughed at -$18.9 million in Q1 2022.
  • A 5-year average of -$1.3 million and a median of -$354000.0 in 2025 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: crashed 1733.66% in 2022 and later soared 2435.05% in 2025.
  • Year by year, Change in Accured Expenses stood at -$1.1 million in 2022, then surged by 202.83% to $1.2 million in 2023, then plummeted by 91.65% to $97000.0 in 2024, then soared by 2435.05% to $2.5 million in 2025, then plummeted by 169.58% to -$1.7 million in 2026.
  • Business Quant data shows Change in Accured Expenses for LCTX at -$1.7 million in Q1 2026, $2.5 million in Q4 2025, and $271000.0 in Q3 2025.